The Most Advanced Heart Failure Care, Anywhere

The only full service, virtual-first Heart Failure clinic focused on medication optimization and volume management.

HekaHeart works alongside your practice – improving outcomes, optimizing financial performance, and empowering your teams to deliver high-impact care.

Improve Patient Outcomes

Ensure patients receive the right treatments at the right time, with real-time monitoring & tailored interventions.

Reduce Clinician Burden

Minimize ‘scut work’ and care between clinic visits through automated administrative tasks and augmented, specialist-level care.

Optimize reimbursable events, reduce readmission penalties, and deliver high-value, patient-centric care.

Drive Financial Performance

HekaHeart’s Virtual Heart Failure Clinic

Scalable Care Platform

AI-driven care platform designed exclusively for heart failure management, focused on the initiation and optimization of Guideline-Directed Medical Therapy (GDMT), volume management, patient engagement, and remote monitoring.

Complete, End-to-End Care

Multidisciplinary Team

Treatment regimens actively managed by cardiac trained NPs & Clinical Pharmacists, with RN-led remote monitoring, patient engagement, access support, and care coordination. 

Our Approach

Integration, Not Disruption

Why Virtual Heart Failure Care?

There is unambiguous evidence and broad consensus that Guideline-Directed Medical Therapy (GDMT) and effective volume management has extraordinary impacts on HF outcomes. Unfortunately, adoption of these proven care strategies remains frighteningly low.

We understand why. Heart Failure care requires hands-on, high-touch patient management. Few systems & practices have the resources, infrastructure, or time to deliver the care our patients need.

HekaHeart’s goal is to fill these care gaps, maximize impact and outcomes, and deliver a tailored patient experience to bring advanced Heart Failure care to all.

22%

of patients receive Triple Therapy recommended by the 2013 Guidelines

10%

of patients receive Quad Therapy recommended by the 2022 Guidelines

1%

of patients receive optimal GDMT dosing

Let’s Transform Heart Failure Care Together

  1. Adapted from Alsumali et al., “Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.” 2021.